HC Wainwright Cuts Minerva Neurosciences (NASDAQ:NERV) Price Target to $7.00

Minerva Neurosciences (NASDAQ:NERV) had its target price lowered by HC Wainwright from $11.00 to $7.00 in a research note published on Thursday, Benzinga reports. HC Wainwright currently has a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.

Separately, StockNews.com cut Minerva Neurosciences from a hold rating to a sell rating in a research note on Friday, February 23rd.

Minerva Neurosciences Trading Up 0.9 %

Shares of Minerva Neurosciences stock opened at $2.37 on Thursday. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49. The firm’s 50 day simple moving average is $2.66 and its two-hundred day simple moving average is $5.30. The firm has a market capitalization of $16.57 million, a price-to-earnings ratio of -0.53 and a beta of 0.27.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.07. On average, sell-side analysts predict that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.